Anxiety, Relapse, Substance Addiction
Conditions
Keywords
Methamphetamine, Coreg, Withdrawal, anxiety, Substance Addiction
Brief summary
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.
Interventions
DRUGCoreg
Sponsors
National Institute on Drug Abuse (NIDA)
Aaron J. Janowsky
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Must have entered treatment into the outpatient Clinical Addiction Rehabilitation Section (CARS) through the US Portland Veterans Affairs Medical Center * Must meet the clinical definition for methamphetamine dependence * Self-reported methamphetamine use within 10 days of entering the study * Must be able to understand and sign the consent form
Exclusion criteria
* Dependent on any other drug except nicotine, caffeine, marijuana and alcohol * Pregnant or nursing mothers * Psychosis * Dementia * Any serious medical condition that could be aggravated by the study protocol (Allergic reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis, Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood sugar, Kidney disease, Liver disease or Overactive thyroid) * History of withdrawal seizures or delirium tremors * Use of MAO inhibitors within the last two weeks * Considerable hepatocellular injury, including cirrhosis of the liver or liver function test levels higher than 2 times normal
Countries
United States
Outcome results
None listed